What is Zenflow?
Zenflow, Inc. operates at the intersection of medical engineering and patient-centric care. Founded by Stanford University Biodesign Fellows, the company specializes in developing minimally invasive solutions for benign prostatic hyperplasia and related urinary conditions. Its flagship Spring technology represents a significant departure from traditional surgical interventions, offering a less traumatic alternative that preserves natural anatomy. As a privately held entity, Zenflow maintains a strong focus on clinical validation and regulatory milestones, positioning itself as a disruptive force within the global urology market.
How much funding has Zenflow raised?
Zenflow has raised a total of $79.4M across 3 funding rounds:
Series A
$31.4M
Series B
$24M
Series C
$24M
Series A (2018): $31.4M with participation from Medical Technology Venture Partners, F-Prime Capital Partners, and Invus Opportunities
Series B (2021): $24M led by F-Prime Capital Partners, SV Tech Ventures, Cloudstone Capital, Invus, Golden Seeds, Medical Technology Venture Partners, and Astia
Series C (2024): $24M supported by Cook Medical, F-Prime Capital Partners, and Invus
Key Investors in Zenflow
F-Prime Capital Partners
A global venture capital firm with a deep focus on healthcare and technology, leveraging a team of doctors and scientists to identify high-impact medical innovations.
Invus
An established investment firm providing strategic consulting and financial support to companies across various sectors, including specialized healthcare services.
Cook Medical
A prominent American manufacturer of medical devices, bringing extensive industry expertise and strategic manufacturing capabilities to its investment portfolio.
What's next for Zenflow?
Looking ahead, Zenflow is poised to transition from its current investigational phase toward broader clinical adoption. The recent strategic backing provides the necessary runway to navigate complex regulatory landscapes and scale manufacturing capabilities. As the company continues to collaborate with global urological experts, the focus will likely shift toward securing commercial approval and establishing the Spring system as a standard-of-care option. Investors remain optimistic that the firm's unique approach to prostate health will yield significant long-term value in the competitive healthtech landscape.
See full Zenflow company page
